Dupixent Specified Drug Use Investigation for long term use (Asthma)

Dupixent Specified Drug Use Investigation for long term use (Asthma) - Dupixent Specified Drug Use Investigation for long term use (Asthma)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036992

Enrollment

300

Registered

2019-06-07

Start date

2019-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients who meet criteria for treatment with dupixent for their asthma according to the indication in Japanese labeling (severe or intractable asthmatic patients with inadequate control in conventional therapies) -Patients who newly start receiving the treatment with Dupixent -Patients who can provide informed consent

Exclusion criteria

Exclusion criteria: -Patients who have been administered Dupixent in the past -Patients who are participating in or have been registered for clinical trials with therapeutic intervention of Dupixent -Patients with a history of hypersensitivity to the ingredients of Dupixent -Patients who are contraindicated in the package insert of Dupixent

Design outcomes

Primary

Measure	Time frame
Safety: Occurrence of cases of eosinophilia over 5000/micro L, and eosinophilia with clinical symptoms	—

Secondary

Measure	Time frame
Safety: Occurrence of adverse drug reactions Effectiveness: Severe asthma exacerbation	—

Countries

Japan

Contacts

Public ContactPublic contact for Drug use surveillance -

Sanofi K.K. Post-authorization regulatory studies, Medical Affairs

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results